Sollinda Capital Management LLC Takes $276,000 Position in Johnson & Johnson (NYSE:JNJ)

Sollinda Capital Management LLC purchased a new position in Johnson & Johnson (NYSE:JNJ - Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 1,665 shares of the company's stock, valued at approximately $276,000.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Tallon Kerry Patrick bought a new position in shares of Johnson & Johnson during the fourth quarter valued at approximately $290,000. Brighton Jones LLC grew its stake in Johnson & Johnson by 13.9% during the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock worth $7,502,000 after buying an additional 6,332 shares during the last quarter. Hudson Value Partners LLC increased its position in Johnson & Johnson by 2.5% in the fourth quarter. Hudson Value Partners LLC now owns 41,403 shares of the company's stock worth $5,648,000 after buying an additional 1,022 shares during the period. West Michigan Advisors LLC lifted its stake in Johnson & Johnson by 12.9% in the fourth quarter. West Michigan Advisors LLC now owns 4,458 shares of the company's stock valued at $645,000 after buying an additional 509 shares during the last quarter. Finally, Metis Global Partners LLC boosted its holdings in shares of Johnson & Johnson by 1.4% during the fourth quarter. Metis Global Partners LLC now owns 140,714 shares of the company's stock valued at $20,350,000 after acquiring an additional 1,956 shares during the period. 69.55% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. Barclays dropped their price objective on shares of Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating on the stock in a report on Thursday, April 17th. Leerink Partners lowered shares of Johnson & Johnson from an "outperform" rating to a "market perform" rating and dropped their price target for the company from $169.00 to $153.00 in a research note on Tuesday, May 13th. Bank of America reduced their price objective on Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating for the company in a research report on Thursday, April 10th. Leerink Partnrs cut Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, May 13th. Finally, Benchmark upgraded Johnson & Johnson to a "strong-buy" rating in a research report on Thursday, April 24th. Eleven analysts have rated the stock with a hold rating, seven have given a buy rating and three have given a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $170.88.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ traded up $0.60 during trading hours on Thursday, hitting $156.16. 1,446,381 shares of the company's stock traded hands, compared to its average volume of 8,020,342. The company's fifty day simple moving average is $153.63 and its two-hundred day simple moving average is $153.88. The company has a market cap of $375.74 billion, a price-to-earnings ratio of 17.37, a price-to-earnings-growth ratio of 2.36 and a beta of 0.41. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.03 and a current ratio of 1.26. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $169.99.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, topping analysts' consensus estimates of $2.59 by $0.18. The firm had revenue of $21.89 billion during the quarter, compared to analysts' expectations of $21.65 billion. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. As a group, equities analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th were issued a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 3.33%. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date of this dividend was Tuesday, May 27th. Johnson & Johnson's dividend payout ratio is currently 57.84%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.